- Home
- ELBM vs LPCN Comparison
ELBM vs LPCN Comparison
Compare ELBM & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELBM
- LPCN
- Stock Information
- Founded
- ELBM 2011
- LPCN 1997
- Country
- ELBM Canada
- LPCN United States
- Employees
- ELBM N/A
- LPCN N/A
- Industry
- ELBM Industrial Machinery/Components
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- ELBM Miscellaneous
- LPCN Health Care
- Exchange
- ELBM Nasdaq
- LPCN Nasdaq
- Market Cap
- ELBM 16.7M
- LPCN 16.1M
- IPO Year
- ELBM N/A
- LPCN N/A
- Fundamental
- Price
- ELBM $0.86
- LPCN $2.89
- Analyst Decision
- ELBM Strong Buy
- LPCN Strong Buy
- Analyst Count
- ELBM 1
- LPCN 2
- Target Price
- ELBM $2.20
- LPCN $9.00
- AVG Volume (30 Days)
- ELBM 130.6K
- LPCN 16.1K
- Earning Date
- ELBM 08-15-2025
- LPCN 11-06-2025
- Dividend Yield
- ELBM N/A
- LPCN N/A
- EPS Growth
- ELBM N/A
- LPCN N/A
- EPS
- ELBM N/A
- LPCN N/A
- Revenue
- ELBM N/A
- LPCN $4,208,119.00
- Revenue This Year
- ELBM N/A
- LPCN N/A
- Revenue Next Year
- ELBM N/A
- LPCN N/A
- P/E Ratio
- ELBM N/A
- LPCN N/A
- Revenue Growth
- ELBM N/A
- LPCN N/A
- 52 Week Low
- ELBM $0.77
- LPCN $2.68
- 52 Week High
- ELBM $2.70
- LPCN $6.17
- Technical
- Relative Strength Index (RSI)
- ELBM 26.53
- LPCN 39.07
- Support Level
- ELBM $0.84
- LPCN $2.86
- Resistance Level
- ELBM $0.93
- LPCN $3.00
- Average True Range (ATR)
- ELBM 0.07
- LPCN 0.12
- MACD
- ELBM -0.01
- LPCN -0.01
- Stochastic Oscillator
- ELBM 26.15
- LPCN 12.28
About ELBM Electra Battery Materials Corporation
Electra Battery Materials Corp is building North America's fully integrated, localized, and environmentally sustainable battery materials park. Electra Battery Materials is an integral part of the North American battery supply chain, providing low-carbon, sustainable, and traceable raw materials for the region's fast growing electric vehicle industry.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.